...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Primary Endpoint Results for Phase 3 BETonMACE Cardio Outcomes Trial were Announced September 30th ****Detailed Trial Data to be Presented at AHA Late Breaking Session Nov 16th & Company Webcast Nov 18th******

Free
Message: Re: Scenario Analysis on end of BETonMACE Phase 3

iconoclast - I follow this story pretty closely and have never heard that the company gets patient by patient data that would allow them to see the eGFR for each patient. I have heard that they do get bulk information that would allow their scientists to see trends for all patients for which they may be able to make educated guesses.

It won't be long now before we see the Top Line data followed up a number of months later with a full data announcement. I sincerely hope the tundup's words of "stunning and unheard of results" in CKD and cognitive function are true and correct. This could literally mean the world to many patients and of course put a few quid in our pockets.

tada

Share
New Message
Please login to post a reply